Prostate Cancer News and reporting on prostate cancer. Mar 16, 2023 FDA Approves Telix Pharmaceuticals' Gallium-Labeled PET Imaging Agent as CDx for Novartis' Pluvicto Mar 15, 2023 Bellicum to Discontinue CAR T-Cell Trials Due to Immune Adverse Events Mar 13, 2023 Germline Tests Lack Utility for Black South African Prostate Cancer Patients, JNCCN Study Finds Mar 13, 2023 Ambrx Raises $78M to Advance Breast and Prostate Cancer Pipeline Mar 3, 2023 Radiopharm Theranostics to Acquire Pharma15 Prostate Cancer Platform Mar 3, 2023 Patients Are Dying Waiting for Pluvicto, but Novartis Can't Make More Pending Facility Approval Premium Mar 1, 2023 Janssen Files for FDA Approval of PARP Inhibitor Combination in Frontline, BRCA-Positive mCRPC Feb 17, 2023 Drugmakers Pushing Frontline PARP Inhibitor Combos for All mCRPC Patients Amid Oncologists' Concerns Premium Feb 14, 2023 Fusion Pharmaceuticals to Acquire Prostate Cancer Radiopharmaceutical Program From RadioMedix Feb 10, 2023 Cedars-Sinai Researchers Leverage Extracellular Vesicles for Prostate Cancer Status Test Premium Feb 2, 2023 Ratio Therapeutics Raises $20M in Series A Financing Feb 1, 2023 Novartis' Oncology Drugs See Solid Growth in Q4 2022 Premium Dec 13, 2022 Novartis' Pluvicto Approved in Europe for PSMA-Positive Castration-Resistant Prostate Cancer Dec 5, 2022 Novartis to Seek Pluvicto Approval in Another Advanced PSMA-Positive Prostate Cancer Setting Nov 21, 2022 Clarity Pharmaceuticals to Evaluate GRPr-Targeting Radiopharmaceutical in mCRPC Trial Nov 14, 2022 Lantheus Licenses Two Late-Stage Radiopharmaceutical Candidates From Point Biopharma Nov 1, 2022 Pfizer's Oncology Unit Posts Flat Sales Growth in Q3 as Blockbuster Ibrance Sees Decline Premium Oct 27, 2022 Keytruda Revenue Climbs 20 Percent in Q3 as Merck Continues Push Into Earlier-Stage Cancer Settings Premium Oct 25, 2022 Pluvicto Sales Ramp up, Kisqali Gains Continue in Q3 for Novartis Premium Oct 21, 2022 PSMA, Tumor Metabolic Volume May Help Refine Pluvicto Use in Prostate Cancer, Study Suggests Premium Load More Breaking News Apollomics Completes SPAC Merger, Begins Public Trading on Nasdaq Ablaze Pharmaceuticals to Develop RayzeBio's GPC3-Targeted Radiotherapy In Brief This Week: Allarity Therapeutics, Immutep, Thermo Fisher Scientific EMA's CHMP Recommends BMS's Breyanzi as Second-Line Lymphoma Treatment Exai Bio, Quantum Leap Healthcare Collaborative Expand Participation in RNA Liquid Biopsy Trial Omega Therapeutics, Roche Partner for Phase I/II Trial in MYC-Driven Hepatocellular Carcinoma
